Larazotide: Side Effects

Safety Overview#

Larazotide acetate has been evaluated in over 800 patients across Phase 1, 2a, 2b, and 3 clinical trials. The safety profile has been consistently favorable, with adverse event rates comparable to placebo in all studies. This is attributable to the peptide's local gut action and minimal systemic absorption.

Adverse Events#

In the Phase 2b trial (342 patients), the overall incidence of adverse events was similar between larazotide (all doses) and placebo. The most common adverse events in both groups were:

• Headache
• Upper respiratory tract infection
• Abdominal pain
• Nausea
• Diarrhea

None of these occurred at significantly higher rates in the larazotide groups compared to placebo, consistent with a drug that has minimal systemic exposure.

Safety Advantages#

Larazotide's local mechanism of action provides inherent safety advantages:

• Minimal systemic absorption: Reduces risk of off-target systemic effects
• No immunosuppression: Unlike many autoimmune disease therapies, larazotide does not suppress immune function
• GI-specific action: Targets only the intestinal epithelial barrier
• Short-acting: The peptide is degraded by GI peptidases after binding

Contraindications and Interactions#

No formal contraindications or drug interactions have been identified. The minimal systemic absorption makes clinically significant drug-drug interactions unlikely.

Safety Profile Context#

Larazotide belongs to the Immune category of research peptides. Understanding the side effect profile of Larazotide is essential for researchers designing clinical protocols and for healthcare providers advising patients. The side effects documented here are based on available clinical trial data and may not represent the complete safety profile.

Reported Side Effects#

The following side effects have been documented in clinical studies of Larazotide. Side effect severity and frequency are based on available clinical data.

Headache#

Severity: mild | Frequency: common

Headache was reported in both larazotide and placebo groups at similar rates, suggesting it may be related to celiac disease rather than the drug itself.

Abdominal pain#

Severity: mild | Frequency: common

Abdominal pain was common in both treatment and placebo groups, consistent with the underlying celiac disease population. No clear dose-related increase with larazotide.

Nausea#

Severity: mild | Frequency: uncommon

Mild nausea was reported at similar rates across larazotide and placebo groups in clinical trials.

Contraindications#

The following contraindications have been identified for Larazotide based on available research and pharmacological considerations:

• Not established -- larazotide is investigational with no formal contraindications defined
• Patients without confirmed celiac disease were not studied and should not extrapolate from these trial results

Individuals with any of these conditions should not use Larazotide without consulting a qualified healthcare provider.

Drug Interactions#

The following potential drug interactions have been identified for Larazotide:

• No drug-drug interactions have been identified. Larazotide acts locally in the gut with minimal systemic absorption, reducing the potential for systemic drug interactions.

Drug interaction studies for Larazotide remain limited. Researchers should exercise caution when combining Larazotide with other compounds and consult relevant pharmacological references.

Related Reading#

• Larazotide overview and research guide
• Larazotide dosing protocols
• Larazotide risks and legal status